Table 2 Comparison of RECIST 1.0, RECIST 1.1, irRC, irRECIST, and iRECIST
From: Are radiologists ready to evaluate true response to immunotherapy?
| Â | CR | PR | SD | PD | Confirmation of PD | New lesions |
|---|---|---|---|---|---|---|
RECIST 1.0 Unidimensional > 10 mm 10 lesions in total, 5 per organ | Disappearance of all lesions |  > 30% decrease from baseline | Neither CR nor PD | 20% increase; no CR, PR, or SD documented before increased disease | Not applicable | PD |
RECIST 1.1 Unidimensional > 10 mm 5 lesions in total, 2 per organ | Disappearance of all lesions |  > 30% decrease from baseline | Neither CR nor PD |  > 20% increase in the nadir of the sum of target lesions (with a minimum a of 5 mm) | Not applicable | PD |
irRC Bi-dimensional 5 mm × 5 mm 15 lesions in total, 5 per organ | Disappearance of all lesions |  > 50% decrease from baseline | Neither CR nor PD |  > 25% increase in the nadir of the sum of target lesions | At least 4 weeks later | Incorporated in the sum of measurements |
irRECIST Unidimensional > 10 mm 5 lesions in total, 2 per organ | Disappearance of all lesions |  > 30% decrease from baseline | Neither CR nor PD |  > 20% increase in the nadir of the sum of target lesions (with a minimum a of 5 mm) | At least 4 weeks after and up to 12 weeks | Incorporated in the sum of measurements |
iRECIST Unidimensional > 10 mm 5 lesions in total, 2 per organ | Disappearance of all lesions |  > 30% decrease from baseline | Neither CR nor PD |  > 20% increase in the nadir of the sum of target lesions (with a minimum a of 5 mm) | At least 4 weeks after and up to 8 weeks | iUPD; not incorporated in the sum becomes iCPD if confirmed |